raising concerns about clinical benefit and increased toxicity in this subgroup. We analyzed a cohort of HCC pts with the aim of evaluating the efficacy and safety of SFN in this specific population. Methods: A cohort of pts with advanced HCC treated with SFN was retrospectively evaluated. Pts were divided into 2 groups: (A) those younger than 70 years-old (y-o) and (B) those who were 70 y-o or older at the time of SFN initiation. Survival (OS) was calculated from the first day of SFN to death or last data record. Time to treatment failure (TTF) due to disease progression or toxicity was calculated from the first to the last day on SFN. TTF and OS were estimated using Kaplan-Meier and curves were compared by log-rank test. Results: We analyzed 226 HCC pts treated with SFN from Oct-2007 to Jan-2017. Group B was comprised of 37 (16.4%) pts, median age 73.5 years (70-85), 75.7% male, 29.7% had HCV, 86.5% Child-Pugh A, 37.8% had extrahepatic spread. Reduced starting dose SFN (< 800 mg/d) was more common in Group B than in Group A (27% vs 11.8%, p ¼ 0.026). No statistically significant differences in OS (7.9 vs 9.8 months, p ¼ 0.534) or TTF (3.5 vs 4.3 months, p ¼ 0.962) were detected between Groups A and B. The incidence of dermatologic adverse events (38.6% vs 34.1%, p ¼ 0.596) and hypertension (7% vs 5%, p ¼ 0.641) did not differ significantly between Groups A and B, respectively. Intolerance leading to SFN discontinuation occurred in 11% and 9.5% of pts in Groups A and B, respectively (p ¼ 0.780). Conclusions: Our findings suggest that the efficacy and the incidence of adverse events were similar in elderly HCC pts treated with SFN when compared to younger pts. Thus, age alone should not be used to determine the therapy of pts with advanced HCC being considered for SFN.
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Relationship between change in a-fetoprotein (AFP) and patient (pt) survival in hepatocellular carcinoma (HCC): A real-world electronic medical records (EMR) database study Background: Serum AFP levels are used as a diagnostic and prognostic marker for pts with HCC. Assessment of the clinical relevance of changes in AFP over time outside of clinical trials is lacking. This study was designed to explore the relationship between changes in AFP levels and overall survival (OS) in a real-world setting. Methods: This retrospective analysis used the IMS Oncology EMR database (US patients, 12/01/2007 (US patients, 12/01/ -12/31/2014 . Eligible pts were diagnosed with HCC, 18þ years old, had at 1 AFP test recorded 60 days prior to 180 days after diagnosis, and received anticancer therapy 180 days after diagnosis. Survival analyses were by Kaplan-Meier method. The gamma-frailty model was used to correlate AFP change utilizing previously-reported definitions of AFP change (above/below 400 ng/mL, 20 ng/mL, 7 ng/mL/month, 620%, 650%) and OS. Results: A total of 907 pts met eligibility criteria (77.3% male, median 65 years of age). Of 697 pts with AFP prior to start of first-line therapy, the 453 (65%) with a baseline AFP <400 ng/mL had an OS of 4.2 months and the 244 (35%) with 400 ng/mL an OS of 2.9 months. An increase in AFP was associated with a decrease in OS in the 278 patients with baseline and first-line therapy (1L) AFP (Table) . Of the 101 pts with an AFP test before start of second line therapy, 32.7% had AFP 400 ng/mL. Relationship between change in AFP and OS. Background: We intended to explore hepatitis B virus (HBV) reactivation after percutaneous radiofrequency ablation (PRFA) for HBV-related hepatocellular carcinoma (HCC) and the impact of antiviral therapy (AVT) on post-PRFA outcomes. Methods: Data on 538 consecutive patients who underwent PRFA for HBV-related early HCC at the Eastern Hepatobiliary Surgery Hospital between 2007 and 2011 were studied. Propensity score matching (PSM) analysis was used to compare the outcomes between the study groups. Recurrence free survival (RFS) and tumor recurrence were endpoints. Post-PRFA viral reactivation, hepatitis, and patterns of tumor recurrence were also observed. Logistic regression, Kaplan-Meier method and Cox proportional regression were used during the analysis.
Results: Viral reactivation developed in 10.8% of patients who underwent PRFA. Patients with HBV reactivation had higher 1-, 3-, and 5-year tumor recurrence rates than patients without viral reactivation after PRFA (46.9%, 81.6% and 81.6% vs 36.0%, 63.5% and 65.4%, P ¼ 0.004). AVT reduced viral reactivation rate (P < 0.001) and decreased 1-,3-,5-year tumor recurrence rate when compared with the no-AVT (30.2%, 58.6% and 61.4% vs 44.1%, 72.6% and 73.0%, P ¼ 0.001). The local recurrence of tumor after PRFA was only associated with tumor diameter (P ¼ 0.010), however, viral reactivation (P ¼ 0.015) and AVT (P < 0.001) were independent risk factors of intrahepatic distant recurrence. Conclusions: HBV could be reactivated after PRFA. Viral reactivation and AVT had opposite impact on intrahepatic distant recurrence but not local tumor progression of HCC patients after PRFA. 
